Alaunos Therapeutics, Inc. Annual Report: A Summary

This guide helps you understand how Alaunos Therapeutics performed this year. Use this "cheat sheet" to decide if the company fits your investment goals.

1. What does this company do? Alaunos has pivoted its entire business model. In 2024, the company discontinued its cell therapy programs to preserve capital. It is now focused exclusively on ALN1003, an oral pill candidate for obesity and metabolic disorders like MASH. The company aims to develop this as a non-hormonal alternative to current injectable treatments. As of December 31, 2024, the company has no commercial products and generates no revenue.

2. Financial performance The company is in the early research stage and does not yet generate revenue. In 2024, Alaunos reported a $4.2 million loss, an improvement from the $34.5 million loss in 2023, largely due to the cessation of cell therapy research. Since its inception, the company has accumulated a deficit of $924.6 million. Operations are currently funded entirely through external capital.

3. Major wins and challenges The company achieved "proof-of-concept" data for ALN1003, with mouse studies showing reductions in body weight and improvements in liver health. The primary challenge ahead is funding the expensive safety and toxicology studies required by the FDA before human clinical trials can commence.

4. Financial health The company’s financial position is critical. With approximately $2.1 million in cash, management has issued a formal warning regarding the company's ability to continue as a going concern. Additionally, the company faces potential delisting from the Nasdaq stock exchange if it fails to meet minimum equity requirements or maintain a share price above $1.00.

5. Key risks

• Single-Asset Dependency: The company’s future is tied entirely to the success of ALN1003. If the drug fails or the company cannot secure a strategic partner, the investment carries a high risk of total loss.
• Dilution: To fund ongoing research, the company will likely issue additional shares, which would reduce the ownership percentage and value of existing holdings.
• Financial Reporting: The company identified "material weaknesses" in its internal financial controls, indicating potential risks in their accounting processes.

6. Future outlook Survival is contingent upon securing a partnership or raising additional capital within the next 6 to 12 months. The Board of Directors has indicated that if these efforts are unsuccessful, the company may be forced to liquidate assets or cease operations. Management is currently prioritizing the completion of research data to increase the company's appeal to potential partners or buyers.

Investor Takeaway: Alaunos is currently a high-risk, speculative venture. Because the company has no revenue, limited cash, and is dependent on a single drug candidate, it is effectively in a "make-or-break" period. Investors should weigh the potential of their obesity drug against the very real possibility that the company may run out of money or be delisted in the near future.